Table 1 Patient characteristics.
Patient number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|---|---|---|---|---|---|---|---|---|
Age (years) | 67 | 34 | 48 | 32 | 34 | 53 | 54 | 29 |
Sex | Male | Female | Male | Male | Female | Male | Male | Female |
Bevacizumab treatment at start of study | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Treatment duration (weeks) at end of study | 52 | 41 | 66 | 67 | 57 | 288 | 112 | 10 |
Treatment dosage | 5 mg/kg 3-weekly | 5 mg/kg 3-weekly | 3.5 mg/kg 3-weekly | 5 mg/kg 2-for 10 weeks; subsequently 2.5 mg/kg 2-weekly | 7.5 mg/kg 2-weekly | 5 mg/kg 3-for 276 weeks; subsequently 2.5 mg/kg 3-weekly | 5 mg/kg 2-weekly for 32 weeks; subsequently 2.5 mg/kg 2-weekly | 2.5 mg/kg 2-weekly |
Treatment discontinuation | No | No | No | Yes | Yes | Yes | No | No |
Follow up time (months) | 8 | 9 | 7 | 8 | 8 | 26 | 12 | 15 |
